We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03640858
Recruitment Status : Recruiting
First Posted : August 21, 2018
Last Update Posted : September 22, 2022
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Chris McIntyre, Lawson Health Research Institute

Tracking Information
First Submitted Date  ICMJE August 14, 2018
First Posted Date  ICMJE August 21, 2018
Last Update Posted Date September 22, 2022
Actual Study Start Date  ICMJE May 8, 2019
Estimated Primary Completion Date January 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 13, 2020)
A change in larger middle molecule induced symptoms as assessed by the LEVIL application [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 46 ]
The primary outcome will be a change (from patient's own baseline) in general well-being, pain, sleep, breathing, energy, appetite, itch, restless legs, and recovery from hemodialysis when using the Theranova dialyzer. These parameters will be measured using the LEVIL an electronic application based visual analog scale.
Original Primary Outcome Measures  ICMJE
 (submitted: August 17, 2018)
A change in larger middle molecule induced symptoms as assessed by the LEVIL application [ Time Frame: Beginning week 1 and ending at the beginning of the dialysis week on week 14. ]
The primary outcome will be a change (from patient's own baseline) in general well-being, pain, sleep, breathing, energy, appetite, and recovery from hemodialysis when using the Theranova dialyzer. These parameters will be measured using LEVIL, an electronic application based visual analog scale.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 13, 2020)
  • A change in larger middle molecule clearance using the Theranova dialyzer [ Time Frame: First treatment of weeks 1, 14, and 46 ]
    The secondary outcome is a change in the clearance of large middle molecules which will be evaluated by measuring levels of beta-2 microglobulin, beta-12 binding globulin, free light chains (kappa, lambda), factor D, fibroblast growth factor 23, and interleukin 6.
  • Correlation between large middle molecules and patient symptoms [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 54 ]
    Another secondary outcome is the relationship between the clearance of large middle molecules and specific symptoms reported by the patients using the LEVIL application.
  • A change in symptoms with a change in dialyzer (usual to Theranova and vice versa) [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 54 ]
    Another secondary outcome is if the time point where symptoms change with a change in dialyzer
  • Effect on microcirculation and/or hemodialysis induced circulatory stress with the Theranova dialyzer [ Time Frame: Beginning week 3 and ending at the end of the dialysis week on week 14 and again week 23 and ending week 46 ]
    Another secondary outcome is the Theranova dialyzer effect on microcirculation and/or hemodialysis induced circulatory stress
Original Secondary Outcome Measures  ICMJE
 (submitted: August 17, 2018)
  • A change in larger middle molecule clearance using the Theranova dialyzer [ Time Frame: First treatment in weeks 1, 3 and 14. ]
    The secondary outcome is a change in the clearance of larger middle molecules which will be evaluated by measuring levels of beta-2 microglobulin in all patients. In addition, the patients from the London Health Sciences Renal Program will have additional testing (measuring levels of beta-12 binding globulin, free light chains (kappa, lambda), factor D, fibroblast growth factor 23, and interleukin 6).
  • Correlation between larger middle molecules and patient symptoms [ Time Frame: Beginning week 3 and ending at the beginning of the dialysis week on week 14. ]
    Another secondary outcome is the relationship between the clearance of larger middle molecules and specific symptoms reported by the patients using the LEVIL application.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
Official Title  ICMJE Interventional Study to Assess the Effect of Expanded Dialysis Using the Theranova Dialyzer on Patient Reported Symptoms Using the London Evaluation of Illness (LEVIL)
Brief Summary Investigators know that many patients who are on dialysis suffer from the burden of unwanted symptoms, which can affect quality of life. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with at least one hemodialysis treatment. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of these toxins in their blood.
Detailed Description

Baxter Canada has an expanded hemodialysis (HDx) membrane called the "Theranova", which is capable of removing solutes of higher molecular weight. Although this clearly has biochemical advantages it is not known at this time if the removal of larger middle molecules can have a direct and immediate effect on patients reported symptoms and quality of life. In short, do be people actually feel better?

Given the way many QoL measurements fluctuate around the dialysis week, the investigators propose to utilize a dynamic tool. The investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL" an application based platform where patients self-report their symptoms with at least one hemodialysis treatment. Reports are generated immediately and in real-time, which cannot be accomplished with other symptom management tools. This allows the investigators to track study changes and benchmark observations to previously established baseline values. The investigators are excited to see if there is an imminent effect on how patients feel using the Theranova dialyzer.

The study is investigator initiated and the principal investigator has secured modest funding from Baxter to allow support for the core study team and the introduction and maintenance of the LEVIL evaluation platform at other centers. Baxter have also provided some dialyzer support, and will work with individual centers to ensure that there is no consumable increment of cost associated with participation.

The study is 60 weeks in length:

  • LEVIL entries with at least one hemodialysis treatment each week for 60 weeks
  • Blood sampling at 4 time points for all participants
  • Implementation of Theranova dialyzer from weeks 5 through 16 and weeks 25 through 48
  • Wash out period from weeks 17 through 24 and weeks 49 through 60
  • Time to recovery question at the first treatment of weeks 1, 16, 24, and 48 for new participants
  • 5-D Pruritus scale and Restless Legs Syndrome rating scale at the first treatment of weeks 1, 16, 24, and 48
  • Echocardiogram prior to starting hemodialysis and at peak stress at baseline (within the first two weeks), with one treatment between weeks 12 to 16 which will occur mid-week, and with one treatment between weeks 44 to 48 which will occur mid-week (LHSC specific)
  • CVInsight monitoring at baseline (within the first two weeks), with one treatment between weeks 2 to 16, 20 to 25, and with one treatment between weeks 44 to 48 (LHSC specific)
  • Non-invasive assessment of cardiovascular risk using the AGE Reader within 1 hour of starting hemodialysis at baseline, with one treatment between weeks 12 to 16, 20 to 24, and with one treatment between weeks 44 to 48 which will occur mid-week (LHSC specific)
  • Five Time Sit to Stand Test & 60-Second Chair Test at the second treatment of weeks 1, 16, 24, and 48
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Study visits take place within the patients' usual hemodialysis unit consistent with their routinely scheduled dialysis sessions. Beginning week 5 and 25 participants use the Theranova dialyzer until the end of the dialysis week on week 16 and 48. Participants answer 9 questions at least at one session regarding symptoms experienced since their last session using the LEVIL application. Furthermore, participants answer a single time to recovery question at the first treatment of weeks 1, 16, 24, and 48 to get more detailed information on recovery time after dialysis in addition to completing the 5-D Pruritus and the Restless Legs Syndrome scales.

Bloodwork is drawn at 4 intervals throughout the study for laboratory evaluation.

Participants have an echo at baseline and between weeks 12 to 16, 20-24 and 44-48 while on the Theranova dialyzer.

In addition to this, participants will have non-invasive monitoring of circulatory stress using the CVInsight contact device.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE End Stage Renal Disease
Intervention  ICMJE Device: Theranova Dialyzer
The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
Study Arms  ICMJE Experimental: Patients receiving hemodialysis
A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
Intervention: Device: Theranova Dialyzer
Publications * Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of Expanded Hemodialysis Using Medium Cut-off Dialyzer on Quality of Life: Application of Dynamic Patient-Reported Outcome Measurement Tool. Kidney Med. 2021 Jul 29;3(6):992-1002.e1. doi: 10.1016/j.xkme.2021.05.010. eCollection 2021 Nov-Dec.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 13, 2020)
120
Original Estimated Enrollment  ICMJE
 (submitted: August 17, 2018)
100
Estimated Study Completion Date  ICMJE March 30, 2023
Estimated Primary Completion Date January 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Chronic hemodialysis patient
  • Must be on hemodialysis for at least 3 months
  • Age ≥18 years
  • Willing and able to give informed consent

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Life expectancy <1 year as estimated by care provider
  • Hemodialysis patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Christopher McIntyre, MBBS DM 5196858500 ext 58502 Christopher.McIntyre@lhsc.on.ca
Contact: Jarrrin Penny, RN BSN 5196858500 ext 58765 Jarrin.Penny@lhsc.on.ca
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03640858
Other Study ID Numbers  ICMJE 1589
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Chris McIntyre, Lawson Health Research Institute
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Lawson Health Research Institute
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Baxter Healthcare Corporation
Investigators  ICMJE
Principal Investigator: Christopher McIntyre, MBBS DM London Health Sciences Centre
PRS Account Lawson Health Research Institute
Verification Date September 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP